People: Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

112.50DKK
10:26am EDT
Price Change (% chg)

kr.-0.50 (-0.44%)
Prev Close
kr.113.00
Open
kr.113.00
Day's High
kr.114.00
Day's Low
kr.112.00
Volume
61,551
Avg. Vol
63,453
52-wk High
kr.136.00
52-wk Low
kr.63.50

Search Stocks

Summary

Name Age Since Current Position

Gerard van Odijk

57 2014 Chairman of the Board

Paul Chaplin

47 2014 President, Chief Executive Officer

Anders Pedersen

63 2014 Deputy Chairman of the Board

Ole Larsen

48 2008 Chief Financial Officer, Executive Vice President

James Breitmeyer

2013 Executive Vice President, Division President of Cancer Vaccine

Peter Kurstein

57 2012 Director

Claus Braestrup

69 2008 Independent Director

Erik Hansen

61 2010 Independent Director

Biographies

Name Description

Gerard van Odijk

Dr. Gerard W. M. van Odijk, M.D. has served as Chairman of the Board of Directors of Bavarian Nordic A/S since April 24, 2014. He has been Independent Member of the Board since 2008. He is President and Chief Executive Officer of Teva Pharmaceutical Europe B.V. and Chairman of the Board of Merus Biopharmaceuticals B.V. He has previously held various senior positions at GlaxoSmithKline (GSK). He holds a Medical Degree from Universiteit Utrecht.

Paul Chaplin

Dr. Paul Chaplin, Ph.D. has been President and Chief Executive Officer of Bavarian Nordic A/S since May 28, 2014. He has previously been Executive Vice President and Division President Infectious Diseases at the Company. In addition, he serves as General Manager of Bavarian Nordic GmbH. He joined the Company in 1999, and was appointed Executive Vice President in 2004. Prior to his employment at Bavarian Nordic, Dr. Chaplin was developing vaccines against infectious diseases in the United Kingdom and Australia for several years. He holds Master of Science degree in Biology and a Doctorate of Philosophy degree in Immunology from Bristol University.

Anders Pedersen

Dr. Anders Gersel Pedersen, M.D. has served as Deputy Chairman of the Board of Directors of Bavarian Nordic A/S since April 24, 2014. He has been Independent Member of the Board since April 27, 2010. He is Executive Vice President of Drug Development at H. Lundbeck A/S. Prior to this, he worked for Eli Lilly for 11 years. Dr. Pedersen is Member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. He chairs the Board of Directors of Lundbeck International Neuroscience Foundation, and serves as Member of the Boards of Lundbeck Cognitive Therapeutics A/S, TopoTarget A/S, ALK-Abello A/S and Genmab A/S (Deputy Chairman). Dr. Pedersen received his Medical Degree and a doctoral degree in Neuro-Oncology from Koebenhavns Universitet. In addition, he holds a Bachelor of Science Degree in Business Administration from Copenhagen Business School.

Ole Larsen

Mr. Ole Larsen has served as Executive Vice President and Chief Financial Officer (CFO) of Bavarian Nordic A/S since July 2008. He previously held the CFO position at Berlingske Tidende and Nordisk Film. He holds a Master of Science degree in Economics & Business Administration.

James Breitmeyer

Mr. James B. Breitmeyer has served as Executive Vice President and Division President of Cancer Vaccine at Bavarian Nordic A/S since February 8, 2013. He served as Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc. from 2006 to 2012. From 2001 to 2006, he served as Chief Medical Officer of Applied Molecular Evolution Inc., a wholly owned subsidiary of Eli Lilly and Co. From 2000 to 2001, he served as President and Chief Executive Officer of the Harvard Clinical Research Institute. From 1991 to 2000, he held a variety of positions at Serono Laboratories Inc., including Chief Medical Officer and Senior Vice President of Research and Development. Prior to Serono, he served as Scientific Advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. He received his Doctor of Medicine degree and a Doctorate of Philosophy degree from Washington University School of Medicine, he is Board certified in Internal Medicine and Oncology and is Author or Co-author of numerous publications.

Peter Kurstein

Mr. Peter Kurstein has served as Member of the Board of Directors at Bavarian Nordic A/S since April 16, 2012. He is President of Radiometer Medical ApS. He has held managerial positions in Radiometer, the latter eight years as President of the company. He has experience on the Boards of Directors of Danish industrial companies. He is also Vice Chairman of the Board of FOSS A/S and Member of the Board of Radiometer Medical ApS. Furthermore, he is Chairman of the Danish-American Business Forum and the Committee of Healthcare under the Confederation of Danish Industries. He holds a Master of Business Administration Degree from Harvard Business School in Boston, the United States.

Claus Braestrup

Mr. Claus Braestrup has served as Independent Member of the Board of Directors of Bavarian Nordic A/S since 2008. He is a former President and Chief Executive Officer of H. Lundbeck A/S. Previously, he held such positions as Vice President of Pharmaceutical Research, President of the CNS Division, and President of the Diabetes, Care Division at Novo Nordisk A/S, and Head of Preclinical Drug Research at Schering AG. Mr. Braestrup is Chairman of the Board of Directors of Probiodrug AG and Member of the Boards of Santaris Pharma A/S, Evolva Holding SA and the University of Copenhagen. He holds a Doctorate of Medicine degree from Koebenhavns Universitet, where he used to serve as Professor in Neuroscience.

Erik Hansen

Mr. Erik Hansen has been Independent Member of the Board of Directors of Bavarian Nordic A/S since April 27, 2010. He also serves as Chairman of the Company's Audit Committee. He is Director at Tresor Asset Advisers and has previously held the positions of Managing Director of Dansk Portefoelje A/S (now Nykredit Asset Management) and Chief Financial Officer of A.P. Moeller-Maersk A/S. Mr. Hansen is Chairman of the Board of Directors of COMX Holding A/S, COMX Networks A/S, DTU Symbion Innovation A/S, NPT A/S, Polaris Management A/S, Polaris Invest II ApS, TT IT A/S and TT IT Ejendomme A/S. He also serves as Deputy Chairman of the Board of Directors of Fertin Pharma A/S, Gumlink A/S and Bagger-Soerensen & Co. A/S, and Board Member of PFA Holding A/S, PFA Pension Forsikringsaktieselskab, Lesanco ApS and Wide Invest ApS. Apart from that, he holds executive positions at Rigas Holding ApS, Rigas Invest ApS, Tresor Asset Advisers ApS, E.K.P. Invest ApS, Berco ApS, BFB ApS and Sirius Holding ApS, among others. Mr. Hansen holds a Master of Science Degree in Finance and Accounting.

Basic Compensation

Options Compensation

Search Stocks